Wells Fargo & Company Theseus Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.12 - $4.18 $2,607 - $5,141	1,230 Added 24.69%	6,211 $25,000
Q3 2023 Nov 13, 2023	SELL	$2.66 - $10.04 $7,256 - $27,389	-2,728 Reduced 35.39%	4,981 $13,000
Q2 2023 Aug 15, 2023	BUY	$7.28 - $11.82 $34,230 - $55,577	4,702 Added 156.37%	7,709 $71,000
Q1 2023 May 12, 2023	BUY	$5.21 - $14.05 $15,666 - $42,248	3,007 New	3,007 $26,000
Q3 2022 Nov 14, 2022	SELL	$5.7 - $8.68 $803 - $1,223	-141 Reduced 81.5%	32 $0
Q2 2022 Aug 12, 2022	SELL	$5.04 - $14.05 $11,723 - $32,680	-2,326 Reduced 93.08%	173 $1,000
Q1 2022 May 16, 2022	SELL	$8.75 - $14.51 $37,406 - $62,030	-4,275 Reduced 63.11%	2,499 $29,000
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $60,830 - $136,089	6,774 New	6,774 $86,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.